Luca Santarelli. Therachon

Fresh from a Pfiz­er buy­out, Lu­ca Santarel­li’s crew has cre­at­ed a new com­pa­ny — bank­ing new funds and steer­ing their lead drug to a piv­otal

Al­most ex­act­ly 3 years since he joined the biotech start­up world as head of Ther­a­chon, the high-pro­file dis­cov­ery sci­en­tist Lu­ca Santarel­li is ready to start …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.